Document:

Exhibit
10.26

 

March
30, 2020

 

AMENDMENT
NO. 1

 

TO

 

REGISTRATION
RIGHTS AGREEMENT

 

This
Amendment No. 1, dated as of March 30, 2020 (the “Amendment”), is entered into by and between AgeX Therapeutics,
Inc., a California corporation (the “Company”) and Juvenescence Limited, a company incorporated in the British
Virgin Islands (“Holder”). Capitalized terms used in this Amendment and not otherwise defined herein shall
have the meanings ascribed thereto in the “Registration Rights Agreement” (as defined below) as amended hereby.

 

WHEREAS,
the Company and Holder are parties to that certain Registration Rights Agreement dated as of August 13, 2019 (the “Registration
Rights Agreement”);

 

WHEREAS,
the Company and Holder are entering into a new Secured Convertible Facility Agreement dated as of the date hereof providing for
a secured loan facility to the Company in the aggregate principal amount of up to US$8,000,000, subject to the terms and conditions
outlined therein (the “2020 Loan Agreement”);

 

WHEREAS,
in connection with entering into the 2020 Loan Agreement, subject to the terms and conditions outlined therein, the Company has
agreed (a) to issue certain shares of common stock, par value $0.0001 per share, of the Company to Holder, and (b) to issue certain
warrants to Holder pursuant to the terms of a Warrant Agreement dated as of the date of this Amendment by and between the Company
and Holder; and

 

WHEREAS,
the Company and Holder have agreed to amend the Registration Rights Agreement as provided herein in order to include the aforementioned
shares of common stock, warrants and shares of common stock issuable upon exercise of the warrants as “Registrable Securities”
thereunder.

 

NOW
THEREFORE, in consideration of the terms and conditions set forth herein and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.
Amendment to Registration Rights Agreement.

 

1.1.
Section 1(e) of the Registration Rights Agreement is hereby deleted and replaced with the following:

 

(e)
“Loan Agreement” means the Loan Facility Agreement between the Company and Holder, dated August 13, 2019.

 

    	 

    	 

    

 

1.2.
Sections 1(g) through 1(i) of the Registration Rights Agreement are hereby deleted and replaced in their entirety with
the following:

 

(g)
“Second Loan Agreement” means the Secured Convertible Facility Agreement between the Company, as borrower thereunder,
Holder, as lender thereunder, and the subsidiaries of the Company named therein, as guarantors, dated as of the date of this Amendment.

 

(h)
“Shares” means, collectively, (i) 19,000 shares of common stock, par value $0.0001 per share, of the Company
issued by the Company upon the Company’s first draw down from the credit line under the Loan Agreement, and (ii) 28,500
shares common stock, par value $0.0001 per share, of the Company to be issued by the Company upon the satisfaction of the conditions
set forth under the Second Loan Agreement.

 

(i)
“Warrants” means, collectively, (i) up to 150,000 common stock purchase warrants governed by that certain Warrant
Agreement between and among the Company and Holder dated August 13, 2019, and (ii) those common stock purchase warrants governed
by that certain Warrant Agreement between and among the Company and Holder dated as of the date of this Amendment, to be issued
in accordance with Clause 3.6 of the Second Loan Agreement at the time of each Advance (as defined in such agreement), in each
case as such number may be adjusted pursuant to the terms thereof.

 

(j)
“Warrant Shares” means shares of common stock, par value $0.0001 per share, of the Company issuable by the
Company pursuant to the exercise of Warrants.

 

2.
Effect. Except as specifically amended by this Amendment, the Registration Rights Agreement shall remain in full force
and effect and is hereby ratified and confirmed.

 

3.
Governing Law. This Amendment shall be governed in all respects by the laws of the State of California, as applied to contracts
entered into in California between California residents and to be performed entirely within California.

 

4.
Counterparts. This Amendment may be executed in any number of counterparts (including by separate counterpart signature
pages), each of which shall be an original, but all of which together shall constitute one instrument. Any counterpart of this
Agreement may be signed by electronic or facsimile, and such electronic or facsimile signature shall be deemed an original signature.

 

[signature
page follows]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

 

	COMPANY:	 
	 	 	 
	AGEX
    THERAPEUTICS, INC.	 
	 	 	 
	By:
    	/s/ Russell Skibsted	 
	 	Russell
    Skibsted,	 
	 	Chief
    Financial Officer	 
	 	 	 
	By	/s/ Judith Segall	 
	 	Judith
    Segall, Secretary	 
	 	 	 
	HOLDER:	 
	 	 	 
	JUVENESCENCE
    LIMITED	 
	 	 	 
	By:
    	/s/
Gregory Bailey	 
	Name:	Gregory
    Bailey	 
	Title:	Authorized
    SignatoryEXHIBIT
4.2

 

DESCRIPTION
OF THE REGISTRANT’S SECURITIES

REGISTERED
PURSUANT TO SECTION 12 OF THE

SECURITIES
EXCHANGE ACT OF 1934

 

As
of March 27, 2020, Guardion Health Sciences, Inc. (“the Company”) had one class of securities registered under Section
12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)—our common stock, par value $0.001
per share (“Common Stock”).

 

Description
of Common Stock

 

The
following description of our Common Stock is a summary and does not purport to be complete. It is subject to and qualified in
its entirety by reference to our Certificate of Incorporation, as amended (the “Certificate of Incorporation”) and
our Bylaws (the “Bylaws”), each of which are incorporated by reference as an exhibit to the Annual Report on Form
10-K of which this Exhibit 4.2 is a part. We encourage you to read our Certificate of Incorporation, Bylaws, and the applicable
provisions of the Delaware General Corporation Law for additional information.

 

Authorized
Capital Shares

 

Our
authorized capital shares consist of 250,000,000 shares of Common Stock, $0.001 par value per share, and 10,000,000 shares of
preferred stock, $0.001 par value per share (“Preferred Stock”). As of March 27, 2020, there were 85,264,962 shares
of Common Stock issued and outstanding. There were no shares of Preferred Stock issued or outstanding as of March 27, 2020.

 

Voting
Rights

 

Holders
of Common Stock are entitled to one vote per share on all matters voted on by the stockholders, including the election of directors.
Our Certificate of Incorporation and Bylaws do not provide for cumulative voting in the election of directors.

 

Dividend
Rights

 

Holders
of Common Stock are entitled to receive dividends, if any, as may be declared from time to time by the Board of Directors (“Board”)
in its discretion out of funds legally available for the payment of dividends subject to the prior rights of holders of Preferred
Stock and any contractual restrictions we have against the payment of dividends on Common Stock.

 

Liquidation
Rights

 

In
the event of our liquidation, the holders of our Common Stock will be entitled to share ratably in any distribution of our assets
after payment of all debts and other liabilities and the preferences payable to holders of shares of Preferred Stock then outstanding,
if any.

 

Applicable
Anti-Takeover Provisions

 

Set
forth below is a summary of the provisions of the Certificate of Incorporation and the Bylaws that could have the effect of delaying
or preventing a change in control of the Company. The following description is only a summary and it is qualified by refence to
the Certificate of Incorporation, the Bylaws and relevant provisions of the Delaware General Corporation Law (“DGCL”).

 

    	-1-

     

    

 

Ability
of Stockholders to Call Special Meetings

 

Our
Certificate of Incorporation and Bylaws provide that stockholders can only call a special meeting if stockholders holding over
50% of all issued and outstanding shares of the Corporation entitled to vote at a meeting do so.

 

Advance
Notice Requirements

 

Our
Bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election
as directors or new business to be brought before meetings of stockholders. These procedures provide that notice of such stockholder
proposals must be timely given in writing to the Secretary of the Company prior to the meeting at which the action is to be taken.
The notice must contain certain information specified in our Bylaws.

 

Blank
Check Preferred Stock

 

Our
Certificate of Incorporation provides for 10,000,000 authorized shares of “blank check” preferred stock, the terms
of which may be determined by our board of directors without obtaining stockholder approval. Undesignated or “blank check”
preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us
by means of a tender offer, proxy contest, merger or otherwise, and to thereby protect the continuity of our management.

 

Exclusive
Forum Provision

 

In
accordance with an exclusive forum provision set forth in the Bylaws, unless the Company consents in writing to the selection
of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (a) any derivative
action or proceeding brought on behalf of the Company, (b) any action asserting a claim of breach of a fiduciary duty owed by
any director, officer or other employee of the Company to the Company or the Company’s stockholders, (c) any action asserting
a claim arising pursuant to any provision of the Delaware General Corporation Law, or (d) any action asserting a claim governed
by the internal affairs doctrine.

Listing

 

The
Common Stock is traded on NASDAQ Global Market under the trading symbol “GHSI”.

 

Transfer
Agent

 

The
Company’s transfer agent is VStock Transfer, LLC.

 

    	-2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]